ClinConnect ClinConnect Logo
Search / Trial NCT06011954

A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection

Launched by ASTELLAS PHARMA KOREA, INC. · Aug 22, 2023

Trial Information

Current as of July 24, 2025

Recruiting

Keywords

Urothelial Cancer Bladder Cancer Enfortumab Vedotin Padcev

ClinConnect Summary

This clinical trial is focused on understanding how well PADCEV Injection works for adults in South Korea who have urothelial cancer, which affects the lining of the bladder. The study will observe patients who are already receiving this treatment along with other medicines their doctors have prescribed. The main goal is to collect information about the outcomes of the treatment and any medical issues that might arise during the study period.

To participate, individuals must be adults receiving PADCEV Injection as part of their cancer care. They will be monitored for up to 48 weeks (about one year) after starting the treatment, and their medical records will be reviewed to track their health and cancer status. If a participant stops the treatment before the 48 weeks are up, their records will still be reviewed for one month after their last dose or until they begin a different cancer medication. This study is important for improving our understanding of how PADCEV Injection affects patients with urothelial cancer.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients who receive treatment with PADCEV Injection, according to the approved local label.
  • Exclusion Criteria:
  • Patients with any contraindication for PADCEV Injection, according to the approved local label.
  • Patients who receive or are going to receive any investigational medicine during the observation period.

About Astellas Pharma Korea, Inc.

Astellas Pharma Korea, Inc. is a leading pharmaceutical company dedicated to advancing healthcare through innovative research and development. As a subsidiary of Astellas Pharma Inc., a global player in the biopharmaceutical industry, the company focuses on delivering novel therapies in areas such as oncology, urology, and immunology. Astellas Pharma Korea is committed to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals to address unmet medical needs. With a strong emphasis on scientific excellence and a patient-centered approach, Astellas Pharma Korea strives to enhance the quality of life for patients in South Korea and beyond.

Locations

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Goyang Si, Gyeonggi Do, Korea, Republic Of

Suwon Si, Gyeonggi Do, Korea, Republic Of

Suwon Si, Gyeonggi Do, Korea, Republic Of

Jeonju Si, Jeonbuk Do, Korea, Republic Of

Busan, , Korea, Republic Of

Busan, , Korea, Republic Of

Busan, , Korea, Republic Of

Busan, , Korea, Republic Of

Daegu, , Korea, Republic Of

Incheon, , Korea, Republic Of

Jeollanam Do, , Korea, Republic Of

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Patients applied

0 patients applied

Trial Officials

Central Contact

Study Director

Astellas Pharma Korea, Inc.

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported